Literature DB >> 9393812

Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs.

S F Little1, B E Ivins, P F Fellows, A M Friedlander.   

Abstract

The protective effects of polyclonal antisera produced by injecting guinea pigs with protective antigen (PA), the chemical anthrax vaccine AVA, or Sterne spore vaccine, as well as those of toxin-neutralizing monoclonal antibodies (MAbs) produced against PA, lethal factor, and edema factor, were examined in animals infected with Bacillus anthracis spores. Only the anti-PA polyclonal serum significantly protected the guinea pigs from death, with 67% of infected animals surviving. Although none of the MAbs was protective, one PA MAb caused a significant delay in time to death. Our findings demonstrate that antibodies produced against only PA can provide passive protection against anthrax infection in guinea pigs.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9393812      PMCID： PMC175745          DOI： 10.1128/iai.65.12.5171-5175.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  27 in total

1.  Purification of factor I and recognition of a third factor of the anthrax toxin.

Authors:  J L STANLEY; H SMITH
Journal:  J Gen Microbiol       Date:  1961-09

2.  Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production.

Authors:  F C BELTON; R E STRANGE
Journal:  Br J Exp Pathol       Date:  1954-04

Review 3.  Anthrax vaccine development: a continuing story.

Authors:  P Hambleton; P C Turnbull
Journal:  Adv Biotechnol Processes       Date:  1990

4.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

5.  Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies.

Authors:  Stephen F Little; Jeanne M Novak; John R Lowe; Stephen H Leppla; Yogendra Singh; Kurt R Klimpel; Burton C Lidgerding; Arthur M Friedlander
Journal:  Microbiology (Reading)       Date:  1996-03       Impact factor: 2.777

6.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

7.  Purification and properties of in vitro-produced anthrax toxin components.

Authors:  D C Fish; B G Mahlandt; J P Dobbs; R E Lincoln
Journal:  J Bacteriol       Date:  1968-03       Impact factor: 3.490

8.  Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity.

Authors:  K R Klimpel; N Arora; S H Leppla
Journal:  Mol Microbiol       Date:  1994-09       Impact factor: 3.501

9.  Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants.

Authors:  B E Ivins; S L Welkos; S F Little; M H Crumrine; G O Nelson
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

10.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157
View more
  81 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

3.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

4.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

5.  An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin.

Authors:  Nam-Kyu Lim; Jung-Hwan Kim; Mee Sook Oh; Sangyoon Lee; Se-Yeon Kim; Keun-Soo Kim; Hyun-Jung Kang; Hyo Jeong Hong; Kyung-Soo Inn
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

6.  Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Authors:  Phillip R Pittman; Susan F Leitman; Julio G Barrera Oro; Sarah L Norris; Nina M Marano; Manmohan V Ranadive; Bonnie S Sink; Kelly T McKee
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

7.  A monoclonal antibody to Bacillus anthracis protective antigen defines a neutralizing epitope in domain 1.

Authors:  Johanna Rivera; Antonio Nakouzi; Nareen Abboud; Ekaterina Revskaya; David Goldman; R John Collier; Ekaterina Dadachova; Arturo Casadevall
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

9.  A plant-produced protective antigen vaccine confers protection in rabbits against a lethal aerosolized challenge with Bacillus anthracis Ames spores.

Authors:  Jessica A Chichester; Slobodanka D Manceva; Amy Rhee; Megan V Coffin; Konstantin Musiychuk; Vadim Mett; Moneim Shamloul; Joey Norikane; Stephen J Streatfield; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

10.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.